# Alpha-Lipoic Acid (R-ALA) - Clinical Longevity Review & Consensus Audit

> **Consensus Verdict**: Alpha-Lipoic Acid (specifically the biologically active R-enantiomer, R-ALA) is an essential mitochondrial enzymatic cofactor for the pyruvate dehydrogenase (PDH) and alpha-ketoglutarate dehydrogenase (a-KGDH) complexes. It functions as a versatile amphipathic antioxidant that regenerates vitamins C and E, restores intracellular glutathione (GSH), enhances insulin-independent GLUT4 translocation, and possesses multi-RCT proof for reversing diabetic peripheral neuropathy (SYDNEY 2 trial).

## 1. Executive Summary & Scores
- **Longevity Evidence Score**: **87/100**
- **Evidence Quality Tier**: **silver**
- **Human Clinical Evidence Strength**: 91/100
- **Primary Longevity Classification**: supplements
- **Safety Margin Score**: 92/100 (Higher is safer)
- **Time Burden**: ~1 minutes/day
- **Estimated Monthly Cost**: inexpensive
- **Adherence Friction**: 2/10 (Lower is easier to sustain)

---

## 2. Biological Mechanisms of Action
High-level Phase 3 RCT validation for microvascular and neurological protection (SYDNEY 2 trial); essential mitochondrial enzymatic cofactor with broad antioxidant recycling synergy.

---

## 3. Canonical Longevity Vector Impacts (The 8 Longevity Pillars)
- **Heart Health & Endothelial Function**: **54/100** [Rank #109 of 133 in Heart] - Effect: Moderate (Endothelial nitric oxide restoration, microvascular dilation)
    - Mechanism: Enhances endothelial nitric oxide synthase (eNOS) activation and prevents superoxide-mediated destruction of NO into cytotoxic peroxynitrite.
- **Brain Longevity & Neuroprotection**: **58/100** [Rank #111 of 141 in Brain] - Effect: Moderate (-51% Peripheral Neuropathy Symptoms in SYDNEY 2 Trial)
    - Mechanism: Lipid- and water-soluble antioxidant that penetrates endoneurial microvessels, improving microvascular blood flow and sensory nerve conduction velocity.
- **Metabolic Flexibility & Glycemic Control**: **72/100** [Rank #56 of 129 in Metabolic] - Effect: Strong (-18% Fasting Glucose, stimulates insulin-stimulated GLUT4 translocation)
    - Mechanism: Stimulates glucose transporter GLUT4 translocation to the sarcolemma via PI3K and AMPK pathways, enhancing glucose disposal independent of insulin.
- **Cancer Defense & DNA Repair**: **32/100** [Rank #71 of 120 in Cancer Defense] - Effect: Mild-Moderate (Quenches lipid peroxyl radicals, prevents DNA oxidative base lesions)
    - Mechanism: Directly neutralizes hydroxyl radicals and hypochlorous acid while chelating transition metals (Fe2+, Cu2+) to prevent Fenton-type mutagenic reactions.
- **Endocrine & Anabolic Balance**: **0/100** [Rank #102 of 120 in Endocrine] - Effect: Neutral
    - Mechanism: Enzymatic antioxidant cofactor with neutral direct steroid action.
- **Chronic Inflammation Reduction**: **66/100** [Rank #88 of 126 in Inflammation] - Effect: Strong (Restores intracellular glutathione pools, suppresses NF-κB nuclear binding)
    - Mechanism: Reduces intracellular oxidized glutathione (GSSG) back to active reduced glutathione (GSH) and directly suppresses NF-κB DNA-binding activity.
- **Bone Density & Connective Matrix**: **18/100** [Rank #97 of 142 in Bone Matrix] - Effect: Mild (Reduces osteoclast oxidative activation)
    - Mechanism: Dampens reactive oxygen species required for RANKL-induced osteoclast differentiation without direct osteoblast matrix stimulation.
- **Cellular Longevity & Autophagy**: **68/100** [Rank #109 of 131 in Cellular] - Effect: Strong (Essential prosthetic group for mitochondrial pyruvate dehydrogenase complex)
    - Mechanism: Covalently binds lipoyl domains of pyruvate dehydrogenase and alpha-ketoglutarate dehydrogenase, ensuring stoichiometric transfer of acyl groups in mitochondrial respiration.

---

## 4. Practical Protocol & Administration Guidelines
- **Standard Clinical Dosage**: Refer to individualized clinical assessment
- **Recommended Timing**: Consistent daily schedule
- **Administration Type**: Behavioral / Compound
- **Recommended Biomarkers to Monitor**: pain, metabolic_health, energy, soreness, bone_density, heart_health

---

## 5. Safety, Contraindications & Drug Interactions
- **Contraindications**: Severe thiamine (Vitamin B1) deficiency (must co-administer B1 to avoid neurological dysfunction in alcohol misuse)
- **Safety Profile**: High Margin - Mild sulfurous odor in urine; Occasional gastric heartburn or nausea; Transient skin rash in sensitive individuals

---

## 6. Peer-Reviewed Human Clinical Trials & Key PMIDs
1. **Alpha-lipoic acid as a metabolic cofactor accelerates pyruvate entry into the Krebs cycle** [PMID: 17998337]
   - Link: https://pubmed.ncbi.nlm.nih.gov/17998337/
2. **Oral treatment with alpha-lipoic acid improves symptomatic diabetic polyneuropathy: the SYDNEY 2 trial** [PMID: 17062803]
   - Link: https://pubmed.ncbi.nlm.nih.gov/17062803/
3. **Alpha-lipoic acid improves insulin sensitivity and non-insulin-mediated glucose disposal in human subjects** [PMID: 23960787]
   - Link: https://pubmed.ncbi.nlm.nih.gov/23960787/
4. **Efficacy and safety of alpha-lipoic acid in the treatment of diabetic polyneuropathy: a meta-analysis** [PMID: 15159495]
   - Link: https://pubmed.ncbi.nlm.nih.gov/15159495/

---

## 7. Canonical Citation & Web Verification
- **Official Web Review**: [Alpha-Lipoic Acid (R-ALA) on LongevityReviews](https://longevityreviews.org/modalities/ala)
- **Last Evidence Calibration**: 2026-09-09
- **Review Policy**: 0% sponsored placements, independent peer-reviewed consensus.